Apricus Biosciences (APRI) Announces The Launch Of Its Topical Treatment For Erectile Dysfunction Vitaros® In The United Kingdom
6/16/2014 7:57:14 AM
SAN DIEGO, June 16, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced the launch of Vitaros®, Apricus' novel topical on-demand treatment for erectile dysfunction ("ED"). Vitaros will be marketed in the United Kingdom by Takeda Pharmaceuticals International GmbH.
Help employers find you! Check out all the jobs and post your resume.
comments powered by